This suggests the presence of an alternative, GLUT1- and glycolysis-independent metabolic pathway for IL-21 production in patients with SLE or potentially cell-intrinsic differences in cTfh17 cells between these groups. This evidence concerns the gene SLC2A1 and systemic lupus erythematosus.